PMID- 29293276
OWN - NLM
STAT- MEDLINE
DCOM- 20180803
LR  - 20181202
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 33
IP  - 4
DP  - 2018 Apr
TI  - A study about immunomodulatory effect and efficacy and prognosis of human 
      umbilical cord mesenchymal stem cells in patients with chronic hepatitis 
      B-induced decompensated liver cirrhosis.
PG  - 774-780
LID - 10.1111/jgh.14081 [doi]
AB  - BACKGROUND AND AIM: The aim of our study was to investigate the immunomodulatory 
      effect and short-term efficacy and long-term prognosis of decompensated liver 
      cirrhosis patients caused by hepatitis B after a double transplantation with 
      human umbilical cord mesenchymal stem cells (hUCMSCs). METHODS: Fifty inpatients 
      were recruited and given the same medical treatments, receiving hUCMSCs injection 
      intravenously. Fifty-three patients (Group B) matched for age, sex, and baseline 
      alanine aminotransferase, aspartate aminotransferase, albumin, total bilirubin, 
      prothrombin time, and model for end-stage liver disease score and Child-Pugh 
      classification, acted as the control group. RESULTS: Interleukin-6 and tumor 
      necrosis factor alpha levels markedly decreased, and interleukin-10 level 
      apparently increased in Group A at 2 and 4 weeks after treatment. Transforming 
      growth factor beta in Group A increased more remarkably at 2 weeks after 
      treatment. T4 cells and Treg cells in Group A were apparently higher than those 
      in Group B at 2 and 4 weeks after treatment, and T8 cells and B cells were 
      significantly lower than those in Group B. Aspartate aminotransferase levels in 
      Group A were dramatically declining at 8 and 12 weeks after treatment. Levels of 
      albumin, total bilirubin, and prothrombin time in Group A were apparently 
      improved from 4 to 12 weeks after treatment. The improvements in model for 
      end-stage liver disease and Child-Pugh scores in Group A were notably superior to 
      those in Group B from 4 to 36 weeks after treatment. There were no remarkable 
      differences in the incidence of developing liver failure throughout the follow-up 
      period, but the mortality rate of Group A was lower than that of Group B. 
      CONCLUSION: This therapeutic method may be an appropriate choice for patients 
      with decompensated liver cirrhosis.
CI  - (c) 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Fang, Xueqing
AU  - Fang X
AD  - Department of Infectious Diseases, Tongling People's Hospital, Tongling City, 
      Anhui Province, China.
FAU - Liu, Liwei
AU  - Liu L
AD  - Cellular Central Laboratory, 105th Hospital of PLA, Hefei, Anhui Province, China.
FAU - Dong, Jing
AU  - Dong J
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Zhang, Junfei
AU  - Zhang J
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Song, Haiyan
AU  - Song H
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Song, Youliang
AU  - Song Y
AD  - Department of Infectious Diseases, Tongling People's Hospital, Tongling City, 
      Anhui Province, China.
FAU - Huang, Yizhe
AU  - Huang Y
AD  - Department of Infectious Diseases, Tongling People's Hospital, Tongling City, 
      Anhui Province, China.
FAU - Cui, Xiaoling
AU  - Cui X
AD  - Department of Infectious Diseases, Tongling People's Hospital, Tongling City, 
      Anhui Province, China.
FAU - Lin, Jian
AU  - Lin J
AD  - Department of Infectious Diseases, Tongling People's Hospital, Tongling City, 
      Anhui Province, China.
FAU - Chen, Congxin
AU  - Chen C
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Liu, Bo
AU  - Liu B
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Chen, Zhaolin
AU  - Chen Z
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Pan, Jingjing
AU  - Pan J
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
FAU - Chen, Xi
AU  - Chen X
AD  - Department of Infectious Diseases, 105th Hospital of PLA, Hefei, Anhui Province, 
      China.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Adult
MH  - Aspartate Aminotransferases/blood
MH  - Bilirubin/blood
MH  - Biomarkers/blood
MH  - Cytokines/blood
MH  - Female
MH  - Hepatitis B, Chronic/*complications
MH  - Humans
MH  - Liver Cirrhosis/diagnosis/etiology/*immunology/*therapy
MH  - *Lymphocyte Subsets
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Middle Aged
MH  - Prognosis
MH  - Prothrombin Time
MH  - Treatment Outcome
MH  - Umbilical Cord/*cytology
OTO - NOTNLM
OT  - cytokine
OT  - decompensated liver cirrhosis
OT  - efficacy
OT  - immunomodulatory
OT  - lymphocyte subsets
OT  - mesenchymal stem cell
OT  - prognosis
EDAT- 2018/01/03 06:00
MHDA- 2018/08/04 06:00
CRDT- 2018/01/03 06:00
PHST- 2017/09/21 00:00 [received]
PHST- 2017/12/10 00:00 [revised]
PHST- 2017/12/18 00:00 [accepted]
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/08/04 06:00 [medline]
PHST- 2018/01/03 06:00 [entrez]
AID - 10.1111/jgh.14081 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2018 Apr;33(4):774-780. doi: 10.1111/jgh.14081.